CEO In Spotlight: SANUWAVE Schedules Four Investor Presentations In September; Message Expected To Highlight $15 Million In New Revenue From UltraMIST®

September 01 09:41 2020
SANUWAVE schedules a busy September presentation schedule. The first event is Wednesday, September 2, 2020 at LD Micro 500..

SANUWAVE (OTCMKTS: SNWV) CEO, Kevin Richardson II, is prepared to explain how the acquisition of Celularity’s UltraMIST® is a transformative event for his company. The four investor presentations planned for September are expected to deliver a simple message to both institutional and retail investors- the acquisition created a transformative and game-changing moment for SANUWAVE.

While shares of the company have traded higher after the announcement, based on the more than $15 million in accretive revenues and $4 million in EBITDA to its yearly run-rate, the market-cap is still ignoring the value from this acquisition. Using average multiples, models should more accurately reflect roughly $0.50 per share after accounting for new revenues and EBITDA earnings. That could mean an up to 117% increase from current levels.

Other value-driving factors are inherent to the deal. The company also secured premium licensing terms for two important biologics, Biovance and Interfyl, creating a comprehensive wound-care treatment platform that can effectively treat patients from discovery to closure. Additionally, an enhanced and trained sales force of roughly 100 people can immediately maximize and cross-sell the combined strength and complementary nature of UltraMIST® and dermaPACE®, SANUWAVE’s flagship device.

Most importantly to the message, the accretive nature of the acquisition is immediate. SANUWAVE is expecting to seize the cross-selling opportunities from roughly 1000 customer accounts with only 15 that overlap.

That story will be told starting on Wednesday, September 2, 2020. (see schedule and link to all events below)

Busy Presentation Schedule In September

SANUWAVE is scheduled to present at four major virtual investor conferences this month. The message is expected to help investors understand the true value behinds this game-changing acquisition for SANUWAVE. It may also tighten the valuation disconnect between current stock price levels that neglect the enormous boost to revenues and EBITDA earnings. 

The September 2020 presentation schedule includes:


The LD Micro 500

Dates: September 1 – 4, 2020 

Company presentation: Wednesday, September 2, 2020, at 8:40 am ET

Format: Corporate presentation and One-on-One Investor Meetings


The Global Chinese Financial Forum-Investing in Innovation

Dates: September 10, 2020

Company presentation: Thursday, September 10, 2020, at 11:15 am PST (2:15 pm ET)

Format: Corporate presentation and One-on-One Investor Meetings


HC Wainwright 22nd Annual Global Investment Conference 

Dates: September 15-16, 2020

Company Presentation: Wednesday, September 16, 2020, at 4:00 pm ET

Format: Corporate presentation and One-on-One Investor Meetings


Lake Street Capital Markets 4th Annual Best Ideas Growth Conference (Big 4) 

Dates: September 17, 2020

Format: One-on-One Investor Meetings


Each presentation will be webcast live and is accessible through the Events section of SANUWAVE Health’s website at, where they will also be archived.

SANUWAVE’s message is expected to resonate with its institutional and retail investor audience. The virtual conferences also provide a forum for the company to highlight the substantial growth opportunities inherent to its acquisition of Celularity’s UltraMIST® assets. Further, SANUWAVE can show competitive differences and advantages compared to industry giants like Johnson & Johnson (NYSE: JNJ) and Medtronic (NYSE: MDT). Medtronic recently reported revenues of more than $550 million from its diabetes group, a number that demonstrates just a portion of the market opportunities for SANUWAVE.

Most notably, the message that SANUWAVE management expects to deliver is powerful. Simply stated, the transformative event provides SANUWAVE with a platform of scale, immediately brings substantial recurring revenue, and gives SANUWAVE an end-to-end advanced wound care product portfolio. The entirety of that platform addresses the entire care pathway and is compelling to patients, providers, and payers.

In other words, the market is ripe for the full product offerings from SANUWAVE…and they appear ready to deliver.


Disclaimers: Blue Hawk Media, LLC is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. The information made available by Blue Hawk Media, LLC is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Blue Hawk Media, LLC be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Blue Hawk Media, LLC, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. This video and its release is to syndicated outlets has been produced through the engagement of a third party, SANUWAVE, Inc., who has hired Blue Hawk Media, LLC to prepare a research and video report for SANUWAVE. The company has compensated Blue Hawk Media, LLC three-thousand-five-hundred dollars to prepare original content, video production , and syndication services .

Media Contact
Company Name: Blue Hawk Media, LLC
Contact Person: Kenny Ellis
Email: Send Email
Country: United States